Genetics

Genomics plc and MassMutual's program enables more policyowners to understand health risks through innovative genetic testing

Retrieved on: 
Tuesday, April 9, 2024
Health, MassMutual, Cardiovascular disease, Face, Prostate cancer, Learning, Disease, Partnership, Atrial fibrillation, Diabetes, Genetics, Risk, Patient, Ageing, DNA, Breast, Insurance, Risk assessment, Privacy, Nursing

OXFORD, England and SPRINGFIELD, Mass., April 9, 2024 /PRNewswire/ -- Genomics plc (Genomics), a healthcare company transforming health through the power of genomics, and MassMutual, a leading mutual life insurance company in the United States, today announced the next phase of their innovative partnership enabling more eligible MassMutual policyowners to gain knowledge about their health in order to make informed, proactive decisions that may help them lead longer, healthier lives. The program offers a genetic risk assessment service to these individuals, providing insight into their personalized risk for eight major diseases. The expansion follows a successful research collaboration in which more than 70% of policyowners who elected to use the risk assessment service reported intent to take preventative actions based on their risk scores, including plans to see their doctor or seek further screening.

Key Points: 
  • The program offers a genetic risk assessment service to these individuals, providing insight into their personalized risk for eight major diseases.
  • Genomics' at-home test studies millions of small variations in DNA, generating polygenic risk scores, that can inform the likelihood of certain conditions.
  • During the initial Genomics and MassMutual research collaboration, 1 in 5 policyowners learned that they are at a higher risk for preventable diseases.
  • MassMutual only receives high-level, anonymized data from Genomics that allows the company to better understand aggregate policyowners' health and behaviors and interest in these types of offerings.

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

Retrieved on: 
Tuesday, April 9, 2024
Shenzhen University, Molecular biology, Immunology, Nature Methods, Advanced technology, Proteome, Ageing, Speech, Genesis (journal), Data analysis, Southern Medical University, Neuroscience, Translation, Human Cell Atlas, Nature Communications, Biochemistry, Neurology, Communication, Transcriptome, Genetics, Research, Genome, Epigenome, Immunity, Microbiology, Metabolome, Diagnosis, Peking University, Health, Conference, GSA, Executive, Cancer, Fudan University, Reproduction, Biology, National academy, Zhejiang University, Medicine

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.

Key Points: 
  • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.
  • With the theme "Technologic Innovation, Scientific Discovery, Translational Application", TICSSO-2 focused on the latest advances in single-cell and spatial omics.
  • On March 31st and April 1st were four online international forums, with one specifically for young researchers.
  • TICSSO-2 is hailed as the largest, most influential, and highest academic conference in the field of single-cell and spatial omics in the world.

Dovetail Genomics Introduces Novel LinkPrep™ NGS Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Genetic variation, Gene, Genetics, Patient, NGS, 3D, Chromatin, Cancer, Genome, Workflow, Genomics, Poster, Chromosomal translocation, Mobile phone

BOSTON, April 9, 2024 /PRNewswire/ -- Dovetail Genomics today announces the debut of its LinkPrep™ NGS technology, showcasing its potential for de novo detection of structural variants and chromatin topology features in cancer. Through its innovative chromatin conformation approach, LinkPrep™ technology exhibits enhanced sensitivity in detecting translocations and intra-chromosomal rearrangements compared to conventional methods, while also identifying SNVs/InDels within a single assay. Unlike traditional Hi-C methods, LinkPrep technology offers a streamlined process, generating sequenceable libraries from initial samples in a single shift. These findings are being presented at the AACR Annual Meeting, April 5-10, in San Diego, Calif.

Key Points: 
  • Unlike traditional Hi-C methods, LinkPrep technology offers a streamlined process, generating sequenceable libraries from initial samples in a single shift.
  • These findings are being presented at the AACR Annual Meeting, April 5-10, in San Diego, Calif.
  • This will improve the discovery and annotation of novel drivers and mechanisms of cancer.
  • Currently undergoing late-stage validation, Dovetail Genomics is actively seeking strategic partnerships to conduct further studies demonstrating its clinical utility across specific cancer indications.

Semios + Agworld Tease The Next Revolution in Ag: Farming Made Simple™

Retrieved on: 
Friday, April 5, 2024
Agriculture, Food, Genetics, AG, Farmer, History, Face, AI

VANCOUVER, BC, April 5, 2024 /PRNewswire/ - Semios + Agworld are thrilled to kick off a groundbreaking teaser campaign today, led by CEO Sumer Johal.

Key Points: 
  • VANCOUVER, BC, April 5, 2024 /PRNewswire/ - Semios + Agworld are thrilled to kick off a groundbreaking teaser campaign today, led by CEO Sumer Johal.
  • This initiative marks a pivotal point in agriculture, ushering in an era where farming becomes easier, thanks to innovative AI technology.
  • The first video launching today is crafted to ignite curiosity and showcase the journey of agricultural advancements from the earliest innovations to today's cutting-edge technologies.
  • Our upcoming product embodies our commitment to leap beyond the current boundaries with AI, striving to make farming simpler for all".

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Retrieved on: 
Friday, March 22, 2024
MYGN, Diagnosis, Genetic testing, Patent, Combinatorics, Genetics, Patient, Neoplasm, Research, DNA, Myriad Genetics, Doctor of Philosophy, Oncology, Medicine, University, MD Anderson Cancer Center, MRD, Intellectual property, FDA, Estate (law), Pharmaceutical industry

U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.

Key Points: 
  • U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.
  • This method describes a key aspect of tumor-informed MRD assays that detect circulating tumor DNA (ctDNA) through sequencing.
  • Specifically, the patented method relates to the manner in which a sample is sufficiently enriched with ctDNA that it can be detected, if present, with high sensitivity and specificity.
  • “The 2016 filing date of this patent—at the advent of MRD development—highlights Myriad’s foresight about the potential role of tumor-derived cell-free DNA in the expanding field of cancer diagnostics,” said Paul J. Diaz, President and CEO, Myriad Genetics.

Redecan Cannabis Launches New Spring Lineup

Retrieved on: 
Thursday, March 21, 2024
Burn, Snow, TLRY, Genetics, Smoke, Girl Scout Cookies, TSX, THC, Tea

Later this Spring, Redecan will debut its new Redees Hemp’d Taster Series and additional new flower.

Key Points: 
  • Later this Spring, Redecan will debut its new Redees Hemp’d Taster Series and additional new flower.
  • This innovative release marks Redecan’s commitment to providing consumers with exceptional cannabis experiences.
  • The Redecan Redees Hemp’d Taster Series will allow consumers to enjoy a variety of distinct indica strains in one convenient 10-pack of straight-cut pre-rolls.
  • You can find Space Age Cake Flower and pre-rolls at authorized cannabis retailers in select regions and retailers across Canada, along with the Redees Hemp’d Taster Series later this Spring.

Gattaca Genomics Welcomes Dr. Gary Harton as Principal Scientific Advisor

Retrieved on: 
Thursday, March 21, 2024
Health, Genetic testing, Entrepreneurship, Biotechnology, Genetics, University, Doctor of Philosophy, Genomics

Florida, March 21, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics , a leader in reproductive health and genetic testing services, is proud to announce the appointment of Dr. Gary L. Harton, PhD, as a consultant and Principal Scientific Advisor.

Key Points: 
  • Florida, March 21, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics , a leader in reproductive health and genetic testing services, is proud to announce the appointment of Dr. Gary L. Harton, PhD, as a consultant and Principal Scientific Advisor.
  • Gary Harton, with a PhD from the University of Kent and a distinguished career spanning several leading genetics and reproductive health organizations, has joined Gattaca Genomics to enhance the company's scientific and research endeavours.
  • ", says Dr. Harton
    "We are incredibly fortunate to have Dr. Gary Harton join our team as a consultant and Principal Scientific Advisor.
  • “The entire Gattaca Genomics team looks forward to working with Dr. Harton and benefiting from his expertise and leadership.”

Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

Retrieved on: 
Wednesday, March 20, 2024
MYGN, PCR, Arm, Genetic testing, Patent, Risk, Genetics, DNA, Snap, Myriad Genetics, Doctor of Philosophy, Medicine, Male, Pharmaceutical industry

11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad’s SneakPeek Snap® products in the U.S through 2040.

Key Points: 
  • 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad’s SneakPeek Snap® products in the U.S through 2040.
  • Consumers place the Snap device on their arm, press the button, and the sample is collected in one to four minutes.
  • “We view this patent grant as recognition of our innovative approach to fetal sex testing using PCR-based techniques with any push-button blood collection device,” stated Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics.
  • “This patent grant promotes SneakPeek Snap exclusivity in the US market through at least 2040 and provides an opportunity for licensing agreements with leading push-button blood collection device suppliers, positioning us as a strategic partner.”

23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

Retrieved on: 
Wednesday, March 20, 2024
23andMe, Genetics, Patient, SAN, Database, Research, Therapy, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-01473 (‘1473) in advanced solid tumors.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-01473 (‘1473) in advanced solid tumors.
  • The target for the new investigational antibody, ULBP6, was discovered through 23andMe’s proprietary research platform, the world's largest recontactable database of de-identified human genetic and phenotypic information.
  • This is the third drug target genetically validated by the 23andMe research platform to enter the clinic in under 4 years.
  • “We are excited to be underway in our study of ‘1473, and we are grateful to the patients participating in this trial.”

23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago

Retrieved on: 
Tuesday, March 19, 2024
23andMe, African Americans, Iron Age, Farmer, Silver, CE, Indigenous peoples, Genetics, Yellow, Harvard University, SAN, Continental Army, City, DNA, History, Metal, Indian Army Public Schools, African, BCE, Late, Bronze Age, Iron

"23andMe's Historical Matches is a technical breakthrough in our ability to accurately detect genetic connections between customers and historical individuals."

Key Points: 
  • "23andMe's Historical Matches is a technical breakthrough in our ability to accurately detect genetic connections between customers and historical individuals."
  • The new Historical Matches feature leverages the same science applied in a more consumer-friendly and approachable way to making these connections.
  • To create this new feature and connect members to Historical Matches, 23andMe identifies segments of DNA that individuals share with the genetic sequences of historical individuals.
  • The feature relies on publicly available data, scientific publications, and the 23andMe relative matching technology to link to these historical individuals.